Why the diagnosis must be specific
COPD is not a single uniform disease. Some patients have emphysema-predominant disease, others have chronic bronchitis, airway inflammation, frequent infection, asthma overlap or major cardiovascular limitation. A treatment pathway developed for one phenotype should not be assumed to apply to all COPD.
Severity should be described using symptoms, exacerbations, oxygen use, spirometry, diffusion capacity, exercise tolerance and CT findings — not only the words “mild,” “moderate” or “severe.”
What a regenerative pathway may involve
Public information in China describes an autologous lung-progenitor-cell pathway for selected chronic lung disease. This involves a different clinical and manufacturing route from a generic MSC infusion. The treating respiratory team must decide whether the patient’s disease pattern and overall health fit the programme.
International access remains subject to direct confirmation, and an initial online enquiry is not an eligibility decision.
Records needed for a meaningful review
- Pulmonology diagnosis and recent clinic notes
- High-resolution chest CT report and images when available
- Spirometry including FEV1, FVC and FEV1/FVC
- DLCO, six-minute walk test and oxygen use if available
- Smoking history and date of cessation
- Exacerbations, infections, sputum cultures and hospital admissions
- Current inhalers, oxygen and pulmonary rehabilitation history
- Major cardiac, cancer and other comorbidity records
The reviewing institution may request additional tests after seeing the initial case summary.
Questions that affect eligibility
- Is the COPD emphysema-predominant or airway-predominant?
- Is the disease stable or currently exacerbating?
- Is there active infection or significant bronchiectasis?
- How impaired are lung function and exercise capacity?
- Is the patient medically fit for sampling, procedures and follow-up?
- What improvement would be clinically meaningful for this patient?
Evidence and limitations
Clinical development in COPD has reported encouraging signals in selected outcomes, but patient selection and long-term evidence remain important. Improvement in one measure does not guarantee broad recovery, and results from a study population may not apply to every patient.
A responsible discussion should include which outcomes are supported, the duration of follow-up, adverse events and uncertainty.
Other treatment options to consider
Optimised inhaled therapy, smoking cessation, vaccination, pulmonary rehabilitation, oxygen where indicated, evaluation for bronchoscopic or surgical lung-volume reduction, and management of cardiac or sleep-related disease may be important. These established options should not be abandoned when exploring regenerative medicine.
Next step for an international patient
Send the diagnosis, most recent CT report, pulmonary-function tests, oxygen use, smoking history and current treatment. We will identify whether the case appears worth formal respiratory review.
Do not stop prescribed treatment, make irreversible travel plans or pay a medical fee until the responsible institution has reviewed the case and issued written instructions.